Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.

Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology (2016) 0.84

Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology (2015) 0.83

Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81

The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers. Oncoimmunology (2015) 0.80

Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer. Transl Lung Cancer Res (2015) 0.78

STAT3 inhibition for cancer therapy: Cell-autonomous effects only? Oncoimmunology (2016) 0.78

Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients. Oncoimmunology (2016) 0.75

NK Cell Subtypes as Regulators of Autoimmune Liver Disease. Gastroenterol Res Pract (2016) 0.75

NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27. Oncotarget (2017) 0.75

Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. Oncoimmunology (2016) 0.75

Immunosuppressive γδ T cells foster pancreatic carcinogenesis. Oncoimmunology (2016) 0.75

T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. Lab Invest (2017) 0.75

Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. Curr Oncol Rep (2017) 0.75

PD-L1 blockade for urothelial carcinoma. Oncoimmunology (2017) 0.75

Novel immune checkpoint blocker to treat Merkel cell carcinoma. Oncoimmunology (2017) 0.75

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53

Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20

Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75

Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00

PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39

Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol (2002) 9.18

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63

Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46

Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23

Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8.17

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11

Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol (2004) 7.16

Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol (2014) 5.89

Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med (2006) 5.88

De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell (2005) 5.79

Oncolytic virotherapy. Nat Biotechnol (2012) 5.79

Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65

Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20

Breakthrough of the year 2013. Cancer immunotherapy. Science (2013) 5.05

Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest (2013) 4.96

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89

Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol (2013) 3.74

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73

The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol (2009) 3.72

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68

The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60

Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 3.10

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06

Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol (2013) 3.01

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med (2014) 2.82

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol (2013) 2.70

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res (2013) 2.62

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med (2014) 2.51

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51

Oncolytic viruses in cancer therapy. Cancer Lett (2007) 2.45

Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol (2009) 2.44

Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev (2008) 2.40

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol (2011) 2.36

The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer (2013) 2.35

Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 2.29

DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer (2008) 2.23

PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res (2012) 2.23

Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer (2008) 2.21

Mechanisms maintaining peripheral tolerance. Nat Immunol (2009) 2.14

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol (2012) 2.14

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA (2014) 2.13

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol (2004) 2.12

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer (2014) 2.08

PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res (2014) 2.06

The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat Rev Immunol (2006) 2.03

Gefitinib--a novel targeted approach to treating cancer. Nat Rev Cancer (2004) 1.92

Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 1.87

Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol (2006) 1.81

Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78

Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol (2014) 1.77

Protein kinase C-η controls CTLA-4-mediated regulatory T cell function. Nat Immunol (2014) 1.76

Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells. Immunol Rev (2008) 1.74

Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med (2009) 1.63

Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014) 1.61

The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol (1999) 1.59

B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A (2011) 1.58

PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol (2014) 1.58

Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability. PLoS One (2014) 1.57

OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res (2013) 1.57

Hemophilia A induced by ipilimumab. N Engl J Med (2011) 1.55

Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55

Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res (2014) 1.54

Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res (2013) 1.51

Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2014) 1.49

Breast and prostate cancer: more similar than different. Nat Rev Cancer (2010) 1.48

Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res (2013) 1.48

Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology (2012) 1.48

PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother (2011) 1.47

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother (2014) 1.42

Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer (2012) 1.41

Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41

IL-10 and TGF-beta induce alloreactive CD4+CD25- T cells to acquire regulatory cell function. Blood (2003) 1.40

Abscopal effect in a patient with melanoma. N Engl J Med (2012) 1.39

Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36

Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07

Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology (2014) 1.01

Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology (2014) 0.91

Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology (2014) 0.90

Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology (2015) 0.84

Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology (2014) 0.84

Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology (2015) 0.83

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology (2015) 0.77